Literature DB >> 7694850

Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway.

D S Holsen1, S Harthug, H Myrmel.   

Abstract

A study was performed in order to determine the prevalence of anti-hepatitis C virus (HCV) antibodies, the risk factors for HCV infection and the markers of hepatic disease in a population of prisoners. Of 101 new prisoners admitted to a Norwegian national prison over a three month period, 70 were included in the study, of whom 32 (46%) were anti-HCV positive. Intravenous drug abuse was the predominant risk factor for HCV infection, although a history of tattooing was found by logistic regression analysis to be a significant risk factor independent of intravenous drug abuse. Most anti-HCV positive prisoners had a history of previous incarcerations. Among the anti-HCV positive subjects, increased alanine aminotransferase (> 50 U/l) was found in 23 (72%). HCV infection was the major cause of hepatic abnormalities in the study population. Only 15 (47%) of the anti-HCV positive prisoners reported knowledge of previous hepatic disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694850     DOI: 10.1007/bf02009378

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Hepatitis C virus transmitted by tattooing needle.

Authors:  N Abildgaard; N A Peterslund
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

2.  Intravenous drug misuse among prison inmates: implications for spread of HIV.

Authors:  S Dye; C Isaacs
Journal:  BMJ       Date:  1991-06-22

Review 3.  [Incidence of hepatitis C in chronic liver diseases following tattooing].

Authors:  K Iwamura; L Prónai; K Nishioka; J Watanabe
Journal:  Orv Hetil       Date:  1992-04-12       Impact factor: 0.540

4.  Seroepidemiologic study of hepatitis B and C viruses in federal correctional institutions in British Columbia.

Authors:  R G Préfontaine; R K Chaudhary
Journal:  Can Dis Wkly Rep       Date:  1990-12-29

5.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.

Authors:  M J Alter; S C Hadler; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; L A Moyer; H A Fields; D W Bradley
Journal:  JAMA       Date:  1990-11-07       Impact factor: 56.272

6.  Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.

Authors:  J Tor; J M Llibre; M Carbonell; R Muga; A Ribera; V Soriano; B Clotet; M Sabriá; M Foz
Journal:  BMJ       Date:  1990-11-17

7.  Hepatitis C virus infection in intravenous drug users: prevalence and risk factors.

Authors:  E Girardi; M Zaccarelli; G Tossini; V Puro; P Narciso; G Visco
Journal:  Scand J Infect Dis       Date:  1990

8.  [Hepatitis A-, B- and C-markers among Norwegian drug addicts in the period 1975-89].

Authors:  K B Kielland; J C Siebke
Journal:  Tidsskr Nor Laegeforen       Date:  1991-03-10

9.  Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden with a second generation test.

Authors:  L Mattsson; L Grillner; O Weiland
Journal:  Scand J Infect Dis       Date:  1992

10.  Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B.

Authors:  A Widell; B G Hansson; E Berntorp; T Moestrup; H P Johansson; H Hansson; E Nordenfelt
Journal:  Scand J Infect Dis       Date:  1991
View more
  18 in total

1.  Prisons as social determinants of hepatitis C virus and tuberculosis infections.

Authors:  Niyi Awofeso
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

2.  Prevalence and correlates of Hepatitis C among injection drug users: The significance of duration of use, incarceration and race/ethnicity.

Authors:  William W Latimer; Sarra L Hedden; Leah Floyd; April Lawson; Alexander Melnikov; S Geoffrey Severtson; Anne-Gloria Moleko; Kristin Cole
Journal:  J Drug Issues       Date:  2009-09

3.  Hepatitis C virus risk factors in the Turkish community.

Authors:  Beytullah Yildirim; Veysel Tahan; Resat Ozaras; Huseyin Aytekin; Ali Mert; Fehmi Tabak; Hakan Senturk
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

4.  Access to treatment of hepatitis C in prison inmates.

Authors:  Paul Strock; Joël Mossong; Karine Hawotte; Vic Arendt
Journal:  Dig Dis Sci       Date:  2008-08-29       Impact factor: 3.199

5.  Survey of French prison found that injecting drug use and tattooing occurred.

Authors:  M Rotily; C Delorme; Y Obadia; N Escaffre; A Galinier-Pujol
Journal:  BMJ       Date:  1998-03-07

6.  Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran.

Authors:  Amir Houshang Mohammad Alizadeh; Seyed Moayed Alavian; Khalil Jafari; Nastaran Yazdi
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

7.  Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system.

Authors:  J D Ruiz; F Molitor; R K Sun; J Mikanda; M Facer; J M Colford; G W Rutherford; M S Ascher
Journal:  West J Med       Date:  1999-03

8.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.

Authors:  P De; E Roy; J-F Boivin; J Cox; C Morissette
Journal:  J Viral Hepat       Date:  2008-01-20       Impact factor: 3.728

9.  HIV and hepatitis C virus testing and seropositivity rates in Canadian federal penitentiaries: A critical opportunity for care and prevention.

Authors:  Prithwish De; Nancy Connor; Françoise Bouchard; Donald Sutherland
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

10.  Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study.

Authors:  Sérgio A de Nishioka; T W Gyorkos; L Joseph; J P Collet; J D MacLean
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.